New drug combo shows promise for tough skin cancers

NCT ID NCT04109456

Completed Disease control Sponsor: InxMed (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 23, 2026 · Updated 21 times

Summary

This early-phase trial tested a new drug called IN10018, alone or with other medicines, in 51 adults with metastatic melanoma (skin cancer that has spread). The main goal was to check safety and how the body handles the drug. Researchers also looked for signs that the drug could shrink tumors. The study included people with two hard-to-treat types: uveal melanoma and NRAS-mutant melanoma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Columbia University Medical Center

New York, New York, 10032, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Linear Clinical Research

Nedlands, Western Australia, Australia
MD Anderson

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
St Vincent Hospital Sydney

Sydney, New South Wales, Australia
Sylvester Comprehensive Cancer Center.

Miami, Florida, 33136, United States
The Alfred Hospital

Melbourne, Victoria, Australia

Conditions

Explore the condition pages connected to this study.

METASTATIC MELANOMA